Background {#Sec1}
==========

In patients with coronary artery disease (CAD), the perfusion of the myocardial tissue is impaired. To mitigate myocardial ischemia, a neovascularization process, which includes the creation of a capillary network in the ischemic myocardium (angiogenesis) and the growth of collateral arteries (arteriogenesis) is initiated to enhance blood flow to the myocardium. Collateral arteries are natural vascular bypasses that can significantly reduce the degree of myocardial ischemia. They develop through the growth of small pre-existing arterioles \[[@CR1]\]. Thus, patients with good collateral circulation have a lower mortality (36 %) than patients with low levels of collateralization \[[@CR1]\]. Patients with CAD are highly heterogeneous in their arteriogenic response, even those with totally occluded arteries \[[@CR2]\], with this variability attributed to genetic and environmental factors \[[@CR3]\]. Collateral vascular growth and angiogenesis are parts of the same process leading to neovascularization. They complement each other: collateral growth and arteriogenesis provide bulk flow to the tissue, and angiogenesis promotes a capillary network that salvages the ischemic area. Angiogenesis and arteriogenesis are driven by distinct, but partially overlapping, cellular and molecular pathways \[[@CR4]\]. In this study we examine putative genetic markers of coronary collateral growth. Our group has previously reported that the p.Pro141Leu polymorphism located in the urokinase-type plasminogen activator gene (*PLAU*), a gene expressed at collateral growth sites during arteriogenesis, is associated with coronary collateral development in patients with severe CAD \[[@CR5]\]. To this end, we performed an association study to relate coronary collateral circulation (CCC) to 22 SNPs corresponding to 10 genes with suspected or demonstrated functional involvement in the process of postischemic neovascularization, and their corresponding haplotypes, in a Spanish cohort of patients with CAD.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

The study was conducted between 2008 and 2012. We evaluated a Spanish cohort of 677 consecutive CAD patients with severe (≥70 %) stenosis who had been scheduled to undergo diagnostic coronary angiography at the Centre Cardiovascular Sant Jordi (CCSJ) or the Hospital Universitari Vall d'Hebron (HUVH) in Barcelona, Spain. The protocol was approved by the Bioethics Committee of the two centers (Ethics Committee of Clinical Research of the HUVH and the Bioethics Committee of the CCSJ), and authorized written consent was obtained from all the subjects. The exclusion criteria were: recent (less than 1 month previously) acute myocardial infarction; anemia; recent angioplasty; prior revascularization by percutaneous coronary intervention; coronary artery bypass surgery; and renal infection, inflammation or chronic failure. Epidemiological and clinical data included hypertension, diabetes mellitus (DM), DM type, hyperlipidemia, smoking history, family history of cardiopathies (FHC), history of angina, angina type and acute myocardial infarctions (AMI); with those not referring to type recorded as present or absent.

Coronary angiography and coronary collateral artery scoring {#Sec4}
-----------------------------------------------------------

Selective coronary angiography was performed using multiple orthogonal projections via the Judkins technique. Injection of the contrast in the donor artery was performed at a sustained high pressure with an automated controlled machine (ACIST CVi Contrast Delivery System®). CCC was assessed angiographically using a "modified" Rentrop's method \[[@CR6]\] without occlusion of the recipient artery. The following scale was used to assess the level of filling of the channels: 0 = no visible filling of any collateral channels; 1 = collateral filling of branches of the vessel to be dilated without any dye reaching the epicardial segment of that vessel (that is, right coronary artery injection showing retrograde filling of septal branches to their origin from the left anterior descending artery, without visualization of the latter occluded artery); 2 = partial collateral filling of the epicardial segment of the vessel being dilated; and 3 = complete collateral filling of the vessel being dilated. In patients with more than one collateral vessel, the highest Rentrop score was recorded.

CAD patients were classified according to the degree of CCC as either poor CCC (Rentrop 0--1) (n = 546) or good CCC (Rentrop 2--3) (n = 131). CCC was assessed by three experienced cardiologists who were blinded to the epidemiological, clinical and genetic data. The degree of agreement in the evaluation of CCC was high among the 3 observers, as determined by the kappa coefficient: κ = 0.987; 95 % confidence interval (95 %CI), 0.953-1.000 (P \< 0.001) using the first 100 angiograms.

SNP selection and genotype analysis {#Sec5}
-----------------------------------

22 SNPs of genes involved in postischemic neovascularization were selected attending the following criteria: a) their suspected or proved functional or/and clinical significance regarding angiogenesis or arteriogenesis when known; b) their location within coding, 5\' or 3\' untranslated, or intronic sequences with known potential sites for factor binding; and c) a minor allele frequency of more than 5 % in the population studied (NCBI). We searched genes directly or indirectly involved in angiogenesis and/or arteriogenesis containing functional polymorphisms. Particularly, *HIF1A* \[[@CR7]--[@CR9]\], *VEGFA* \[[@CR10]--[@CR12]\], *KDR* \[[@CR13], [@CR14]\], *NOS3* \[[@CR15], [@CR16]\], *TGFB1* \[[@CR17]--[@CR19]\] and *LGALS2* \[[@CR20], [@CR21]\] have been involved in both processes. Furthermore, *CCL2* \[[@CR22]\] and *ICAM1* \[[@CR23]\] play an important role in arteriogenesis, while *CD53*, which controls TNFα levels \[[@CR24]\], also plays an important role in this process \[[@CR25]\]; and *POSTN* has been reported to be involved in angiogenesis \[[@CR26]\] (Table [1](#Tab1){ref-type="table"}). The SNPs located in or near these genes that were analyzed in this study are listed in Table [1](#Tab1){ref-type="table"} and details of them are as follows. *HIF1A* rs11549465 and rs2057482 affect mRNA production and are associated with CAD \[[@CR27]\]; the first is also related to collateral circulation \[[@CR28]\]*. VEGFA* rs2010963, rs1570360 and rs699947 influence protein production \[[@CR29]\], and along with rs3025039 and rs833061 they have also been related to VEGFA serum levels \[[@CR30]--[@CR32]\]. Moreover, *VEGFA* rs2010963 and rs699947 have been associated with collateral circulation \[[@CR33]\] and CAD \[[@CR34]\]. *KDR* rs1870377 and rs2305948 affect primary protein structure, whereas rs2071559 is located 5' upstream, being all related to CAD \[[@CR35]\]. *CCL2* rs1024611 affects mRNA production \[[@CR36]--[@CR38]\]; and along with rs1024610, MCP1 plasma levels \[[@CR39]--[@CR41]\]. *CCL2* rs1024611 and rs1024610 have been associated with myocardial infarction \[[@CR39], [@CR42]\]. *NOS3* rs1799983 has functional consequences for the protein \[[@CR43], [@CR44]\] which are associated with coronary arteriogenesis \[[@CR45], [@CR46]\] and CAD \[[@CR47]\]. *ICAM1* rs5498 affects the primary structure of the protein and both it and rs3093030, located near the 3' end of the gene, are related to sICAM1 plasma levels \[[@CR48]--[@CR51]\] and to coronary artery calcification \[[@CR52]\]. *TGFB1* rs1800469 is located towards the 5' end of the gene and has been associated with coronary heart disease complications \[[@CR53]\]. *CD53* rs6679497 is an intronic polymorphism associated with TNFα levels \[[@CR24]\] which plays a role in modulating arteriogenesis \[[@CR25]\]. *POSTN* rs3829365 and rs1028728 are located in the 5' UTR of the gene, with the first being associated with heart failure \[[@CR54]\]. Finally, *LGALS2* rs7291467 is located in intron 3 and has been associated with arteriogenesis \[[@CR21]\] and CAD \[[@CR55]--[@CR57]\].Table 1**SNPs analyzed in the study**GeneRole in angiogenesis/arteriogenesisSNPOther HGVS namesLocationFunctional categoryFS scoreAssociation to CCCAssociation to CADFunctional relevance*HIF1A*Both \[[@CR7], [@CR8]\]rs11549465p.Pro582SerExon 2Missense variant0.627\[[@CR28]\]\[[@CR27]\]Influences transactivation activity \[[@CR27], [@CR58]\]rs2057482c.\*45 T \> C3'-UTR3' UTR variant0-\[[@CR27]\]Influences transactivation activity \[[@CR27]\]*VEGFA*Both \[[@CR10]--[@CR12]\]rs2010963c.-634C \> GPromoterRegulatory region variant0.257\[[@CR33]\]\[[@CR34]\]Influences protein production \[[@CR29]\] Related to VEGFA serum levels \[[@CR30]\]rs1570360c.-1154A \> GPromoterRegulatory region variant0.242\--Influences protein production and related to VEGFA serum levels \[[@CR31]\]rs699947c.-2055A \> CUpstream geneRegulatory region variant0.176\[[@CR33]\]\[[@CR34]\]Influences protein production and related to VEGFA serum levels \[[@CR30], [@CR31]\]rs3025039c.\*237C \> T3'-UTR3' UTR variant0\--Related to VEGFA serum levels \[[@CR32]\]rs833061c.-958C \> TPromoterRegulatory region variant0.282\--Related to VEGFA serum levels \[[@CR30]\]*KDR*Both \[[@CR13], [@CR14]\]rs1870377p.Gln472HisExon 11Missense variant0.103-\[[@CR35]\]-rs2305948p.Val297IleExon 7Missense variant0.621-\[[@CR35]\]-rs2071559c.-906 T \> CPromoter flankingRegulatory region variant-\[[@CR35]\]-*CCL2*Arteriogenesis \[[@CR22]\]rs1024611g.2493A \> GPromoter flankingRegulatory region variant0.208-Related to myocardial infarction \[[@CR39], [@CR42]\]Related to MCP1 serum levels \[[@CR39]--[@CR41]\]\
Influences mRNA expression \[[@CR36]--[@CR38]\]rs1024610g.2936 T \> APromoter flankingRegulatory region variant0.158-Related to myocardial infarction \[[@CR39]\]Related to MCP1 serum levels \[[@CR39]\]rs2857657g.5837G \> CNon coding exonNon coding transcript exon variant0.176\-\--rs2857654g.2236C \> APromoter flankingRegulatory region variant0\-\--*NOS3*Both \[[@CR15], [@CR16]\]rs1799983p.Asp298GluExon 7Missense variant1\[[@CR45], [@CR46]\]\[[@CR47]\]Influences activity by different susceptibility to cleavage \[[@CR43], [@CR44]\]*ICAM1*Arteriogenesis \[[@CR23]\]rs5498p.Lys469GluExon 2Missense variant0.092-Related to coronary artery calcification \[[@CR52]\]Related to s-ICAM1 levels \[[@CR48]--[@CR50]\]rs3093030c.-286C \> TNon coding exonNon coding transcript exon variant0.208\--Related to s-ICAM1 levels \[[@CR49], [@CR51]\]*TGFB1*Both \[[@CR17]--[@CR19]\]rs1800469c.\*309 T \> CPromoterRegulatory region variant0.208-\[[@CR53]\]-*CD53*-rs6679497c.-17-5027C \> GIntron 2Regulatory region variant\--Associated to TNFα levels \[[@CR24]\], which has been related to arteriogenesis \[[@CR25]\]*POSTN*Angiogenesis \[[@CR26]\]rs3829365c.-33C \> GPromoter flankingRegulatory region variant0-Associated with heart failure \[[@CR54]\]-rs1028728c.-953 T \> APromoter flankingRegulatory region variant0.5\-\--*LGALS2*Both \[[@CR20], [@CR21]\]rs7291467c.6 + 3279C \> TIntron 1Regulatory region variant\[[@CR21]\]Related to myocardial infarction \[[@CR55]--[@CR57]\]-Abbreviations: CCC, coronary collateral circulation; CAD, coronary artery disease. FS score: functional effects of SNPs obtained from 16 bioinformatics tools and databases. (<http://compbio.cs.queensu.ca/F-SNP/>)

Blood samples were drawn from patients undergoing coronary artery catheterization. Genomic DNA was isolated using the QIAmp DNA Blood kit following the manufacturer's protocol (Qiagen©, UK). TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) were performed to determine genotypes from the blood samples using a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Genotype assessments were reproduced in three independent assays.

Statistical Analysis {#Sec6}
--------------------

Data were summarized and presented in the form of mean, standard deviation and percentage as descriptive statistics. Continuous data that were not normal-distributed were analyzed using the Mann--Whitney *U* test. In this study, age does not show a normal distribution (Shapiro-Wilk p-value \<0.001). Associations among categorical data were assessed using Fisher's exact or chi-square test, and Hardy Weinberg equilibrium was assessed using the chi-square test. Multivariate logistic regression models were adjusted using clinically relevant variables to estimate odds ratios (ORs) and 95 %CIs among genotypes, haplotypes and the risk of poor CCC. Interaction terms between SNPs, haplotypes and significant covariates were also analyzed in the multivariate regression models. Statistical analysis was performed using STATA 11.2 software. The power to detect a genetic association was estimated using the same statistical package. The SNPStats software available at <http://bioinfo.iconcologia.net/en/SNPStats_web> was used to calculate linkage disequilibrium (measured as Lewontin's D0-values) between SNPs, to estimate haplotype frequencies, and to evaluate haplotype association with CCC.

Results {#Sec7}
=======

A total of 677 CAD patients (median of age 66 years, 107 females/570 males) stratified according to the level of coronary collateralization (546 poor; 131 good) were enrolled in the study. The clinical and epidemiological parameters of the patients according to CCC development are listed in Table [2](#Tab2){ref-type="table"}. Statistical analysis showed that there were no differences among the poor and good CCC groups in terms of age, gender, hypertension or hyperlipidemia history, smoking, angina history or previous myocardial infarction (Table [2](#Tab2){ref-type="table"}). However, the incidence of DM (55.9 %) and the percentage of patients prescribed with statins (44.3 %) were significantly higher in the poor CCC group, with p values of 0.037 and 0.035 respectively (Table [2](#Tab2){ref-type="table"}).Table 2**Epidemiological and Clinical Characteristics of CAD patients with poor and good CCC**CharacteristicPoor CCCGood CCCp valuen = 546 (%)n = 131 (%)Age *(years)*65.26 ± 10.8866.76 ± 10.060.187Gender *(male)*460 (84.25)110 (83.97)0.937Hypertension *(n)*372 (68.13)97 (74.05)0.188Diabetes mellitus *(n)*146 (26.74)47 (35.88)0.037\*Hyperlipidemia *(n)*381 (69.78)96 (73.28)0.430Smoking *(n)*126 (23.08)33 (25.19)0.608Angina history *(n)*383 (70.15)93 (70.99)0.849Previous myocardial infarction *(n)*196 (35.90)43 (32.82)0.509Medication with statins *(n)*188 (34.43)58 (44.27)0.035\*Abbreviations: CCC, coronary collateral circulation. Values are given as mean (S.D.) or numbers of patients (%). p \<0.05 was considered as statistically significant (\*)

None of the SNPs studied, with the exception of *NOS3* rs1799983 and *POSTN* rs3829365, showed any deviation from Hardy--Weinberg equilibrium (HWE) (tested by conventional *χ*2) (Table [3](#Tab3){ref-type="table"}). Therefore, rs1799983 (P~HWErs1799983~ = 0.0157) and rs3829365 (P~HWErs3829365~ = 0.0000) were not included in further genetic association tests.Table 3Association of genotype and allele distribution of examined polymorphisms with CAD patients with poor and good CCCGenedbSNP IDPatientsnGenotype count (frequency)P value^a^Allele count (frequency)P value^b^HWE P*VEGFA*rs2010963GGGCCCGCPoor CCC531247 (46.52)224 (42.18)60 (11.30)0.5760718 (67.61)344 (32.39)0.4950.8216Good CCC12150 (41.32)58 (47.93)13 (10.75)158 (65.29)84 (34.71)rs1570360GGGAAAGAPoor CCC451207 (45.90)197 (43.68)47 (10.42)0.782611 (67.74)291 (32.26)0.5210.8494Good CCC9747 (48.45)42 (43.30)8 (8.25)136 (70.10)58 (29.90)rs699947CCACAACAPoor CCC494138 (27.94)245 (49.59)111 (22.47)0.816521 (52.73)467 (47.27)0.9680.5199Good CCC10431 (29.81)48 (46.15)25 (24.04)110 (52.90)98 (47.12)rs3025039CCCTTTCTPoor CCC498386 (77.51)106 (21.29)6 (1.20)0.665878 (88.15)118 (11.85)0.7140.9533Good CCC10584 (80)19 (18.10)2 (1.90)187 (89.05)23 (10.95)rs833061CCCTTTCTPoor CCC526124 (23.57)268 (50.95)134 (25.48)0.471516 (49.05)536 (50.95)0.2320.6392Good CCC12133 (27.27)63 (52.07)25 (20.66)129 (53.31)113 (46.69)*KDR*rs1870377TTATAATAPoor CCC496291 (58.67)178 (35.89)27 (5.44)0.613760 (76.61)232 (23.39)0.3280.8991Good CCC10667 (63.21)35 (33.02)4 (3.77)169 (79.72)43 (20.28)rs2305948CCCTTTCTPoor CCC582487 (83.68)88 (15.12)7 (1.20)0.1991062 (91.24)102 (8.76)0.2070.3210Good CCC153120 (78.43)32 (20.92)1 (0.65)272 (88.89)34 (11.11)rs2071559TTCTCCTCPoor CCC544147 (27.02)276 (50.74)121 (22.24)0.319570 (52.39)518 (47.61)0.1400.8355Good CCC12929 (22.48)64 (49.61)36 (27.91)122 (47.29)136 (52.71)*CCL2*rs1024611AAAGGGAGPoor CCC576332 (57.64)210 (36.46)34 (5.90)0.221874 (75.87)278 (24.13)0.8260.3186Good CCC15394 (61.44)46 (30.06)13 (8.50)234 (76.47)72 (23.53)rs1024610AAATTTATPoor CCC516312 (60.47)180 (34.88)24 (4.65)0.516804 (77.91)228 (22.09)0.7150.6077Good CCC11268 (60.71)36 (32.15)8 (7.14)172 (76.79)52 (23.21)rs2857657CCCGGGCGPoor CCC511309 (60.47)181 (35.42)21 (4.11)0.365799 (78.18)223 (21.82)0.8320.8093Good CCC11171 (63.96)33 (29.73)7 (6.31)175 (78.83)47 (21.17)rs2857654CCACAACAPoor CCC580336 (57.93)211 (36.38)33 (5.69)0.248883 (76.12)277 (23.88)0.9930.4284Good CCC15393 (60.78)47 (30.72)13 (8.50)233 (76.14)73 (23.86)*NOS3*rs1799983GGGTTTGTPoor CCC513211 (41.13)216 (42.11)86 (16.76)0.596638 (62.18)388 (37.82)0.6860.0157\*Good CCC11046 (41.82)48 (43.64)16 (14.54)140 (63.64)80 (36.36)*ICAM1*rs5498AAAGGGAGPoor CCC516136 (26.36)246 (47.67)134 (25.97)0.308518 (50.19)514 (49.81)0.9580.1039Good CCC11233 (29.46)46 (41.08)33 (29.46)112 (50.00)112 (50.00)rs3093030CCCTTTCTPoor CCC517134 (25.92)248 (47.97)135 (26.11)0.415516 (49.90)518 (50.10)0.8830.1535Good CCC11233 (29.46)47 (41.97)32 (28.57)113 (50.45)111 (49.55)*TGFB1*rs1800469GGGAAAGAPoor CCC483198 (50.00)228 (47.20)57 (11.80)0.696624 (64.60)342 (35.40)0.9790.8844Good CCC10043 (43.00)43 (43.00)14 (14.00)129 (64.50)71 (35.50)*CD53*rs6679497GGGAAAGAPoor CCC483198 (41.00)228 (47.20)57 (11.80)0.826624 (64.60)342 (35.40)0.5720.6712Good CCC10043 (43.00)43 (43.00)14 (14.00)129 (64.50)71 (35.50)*POSTN*rs3829365GGGCCCGCPoor CCC405357 (88.15)22 (5.43)26 (6.42)0.795736 (90.86)74 (9.14)0.5350.0000\*Good CCC7669 (90.79)3 (3.95)4 (5.26)141 (92.76)11 (7.24)rs1028728AAATTTATPoor CCC389242 (62.21)128 (32.91)19 (4.88)0.230612 (78.66)166 (21.34)0.1050.7373Good CCC7754 (70.13)22 (28.57)1 (1.30)130 (84.42)24 (15.58)*LGALS2*rs7291467AAAGGGAGPoor CCC581160 (27.54)292 (50.26)129 (22.20)0.106612 (52.67)550 (47.33)0.0800.9589Good CCC15137 (24.50)68 (45.03)46 (30.47)142 (47.02)160 (52.98)*HIF1A*rs11549465CCCTTTCTPoor CCC518402 (77.60)111 (21.43)5 (0.97)0.563915 (88.32)121 (11.68)0.4740.4122Good CCC11284 (75)26 (23.21)2 (1.79)194 (86.61)30 (13.39)rs2057482CCCTTTCTPoor CCC497339 (68.21)148 (29.78)10 (2.01)0.490826 (83.10)168 (16.90)0.3280.1151Good CCC11170 (63.06)38 (34.24)3 (2.70)178 (80.18)44 (19.82)^a^Fisher's exact test was used to evaluate differences between genotype groups. ^b^Pearson's chi-squared, *χ*^2^, was used for to evaluate the allele distribution. \*p \<0.05 was considered as statistically significant

The genotype and allele distributions of all the polymorphisms in the population studied are shown in Table [2](#Tab2){ref-type="table"}, and they did not show any differences between patients with good collateralization and patients with poor collateralization (p ≥0.05) (Table [3](#Tab3){ref-type="table"}). Haplotype association analysis of polymorphisms in strong LD has more power than single locus tests to detect gene--disease associations. Thus, we also checked for haplotype combinations of polymorphisms in the *VEGFA*, *KDR*, *CCL2*, *ICAM1*, and *POSTN* genes to detect associations with CCC. To this end, we first estimated LD between the polymorphisms of these genes. There was a strong pairwise LD between the SNPs within these genes (data not shown), and *VEGFA*, *KDR*, *CCL2*, *ICAM1* and *POSTN* haplotype analysis showed that the haplotype frequencies in patients with good collaterals were similar to those in patients with poor CCC (data not shown).

Discussion {#Sec8}
==========

An increasing number of SNPs are being accepted as underlying contributors to numerous cardiovascular disorders. Different researchers have shown the importance of several polymorphisms in CCC susceptibility \[[@CR21], [@CR28], [@CR33], [@CR46], [@CR47]\]. *In vitro* studies have suggested that the p.Asp298Glu polymorphism plays a functional role, with the Asp 298 variant being associated with a decreased eNOS activity \[[@CR43], [@CR44]\], the consequences of which may include impaired collateral development. The Asp variant has been associated with poor CCC in 291 CAD patients with chronic coronary occlusions \[[@CR45]\], and similar results have been reported in a series of 477 CAD patients with high-grade coronary stenosis ≥70 % \[[@CR46]\]. However, because *NOS3* p.Asp298Glu deviates from HWE in our population, we could not analyze this polymorphism in our samples.

Another polymorphism which has been studied in relation to coronary arteriogenesis is p.Pro582Ser located in the *HIF1A* gene. The C/T polymorphism at nucleotide 85 of exon 12 results in a Pro/Ser polymorphism at residue 582 of HIF-1α. This substitution alters the amino acid sequence in the carboxyl-terminal domain of HIF-1α, which regulates protein stability and transcriptional activity \[[@CR58]\]. Resar et al. demonstrated that CT or TT genotypes affecting residue 582 of the HIF-1α protein were associated with the absence of coronary collaterals in 100 patients with CAD \[[@CR27]\]. This result indicates that p.Pro582Ser substitution could influence the expression of angiogenic growth factors, thus leading to reduced collateral formation. Although we could not validate these results in our 677 CAD patients, our results are in agreement with those published by Alidoosti et al. (2011) which found no association between rs11549465 variants and the extent of CCC (n = 196) \[[@CR59]\]. Despite that study being conducted in Iranian CAD patients, our results support Alidoosti's observations, with our study being more robust based on a significantly higher number of patients (n = 677). Taking all this into account, the relevance of p.Pro582Ser *HIF1A* to CCC susceptibility is still under debate.

Unlike the results reported by Lin et al., 2010, showing that the *VEGFA* c.-634C \> G (+405C \> G) (rs2010963) and c.-2055A \> C (A-2578C) (rs699947) polymorphisms were associated with the coronary arteriogenic response in 393 CAD patients \[[@CR33]\], our results do not confirm the existence of any association between CCC and the allelic or genotypic distribution of this polymorphism. Given that the study by Lin et al. was conducted in Chinese patients, this discrepancy could be attributed to differences in population genetics.

Galectin-2, which is encoded by the *LGALS2* gene, is an inhibitor of arteriogenesis \[[@CR21]\]. This inhibition is dependent of the gene expression on the cell surface of monocytes, acting as a modulator of monocyte/macrophage responses during collateral artery growth. CAD patients with poor CCC have increased monocytic mRNA expression of galectin-2, independent of different stimulations of these cells. Interestingly, the mRNA expression of galectin-2 was significantly associated with the *LGALS2* rs7291467 genotype, which has been associated with CCC in a small group of patients (n = 50) \[[@CR21]\]. The same researchers also found that galectin-2 was able to inhibit collateral circulation in a mouse model of limb ischemia \[[@CR21]\]. However, we have being unable to demonstrate an association between arteriogenic response and the allelic or genotypic distribution of this polymorphism in our cohort of patients. This may be attributable to the fact that van der Laan's study used the collateral flow index as a quantitative measure of CCC, instead of poor and good CCC based on a qualitative angiographic Rentrop score.

The most extensively studied chemokine contributing to postischemic neovascularization is the monocyte chemo-attractant protein-1 (MCP-1); a protein which is overexpressed in collateral growth, allowing for monocyte recruitment sites \[[@CR60]\]. The crucial role of monocytes in collateral growth is exemplified by the observations that genetic targeting of the MCP-1 gene (*CCL2*) and of the MCP-1 receptor gene (*CCR2*) leads to defective collateral growth \[[@CR61], [@CR62]\]. However, none of the SNPs of *CCL2*, rs2857654, rs1024611, rs1024610 and rs2857657, analyzed individually or their haplotype combinations were associated with CCC development.

The main limitation of the study is that the collateralization assessment is based on the angiographic Rentrop score, which is a qualitative rather than a quantitative technique. A modified Rentrop method without occlusion of the recipient artery was performed in the current work. This method, as well as the inclusion of a large portion of patients with subocclusive lesions (\>70-100 %), probably might explain why such a relative low number of patients displayed well-developed collateral arteries in this cohort. Also, functional polymorphims in interferon-beta signaling genes, which are involved in arteriogenesis from clinical studies \[[@CR63], [@CR64]\], were not included in the study.

Conclusions {#Sec9}
===========

Despite having previously reported that *PLAU* p.Pro141Leu (rs2227564) was associated with coronary arteriogenesis \[[@CR5]\], none of the rs11549465, rs2057482, rs2010963, rs1570360, rs699947, rs3025039, rs833061, rs1870377, rs2305948, rs2071559, rs1024611, rs1024610, rs2857657, rs2857654, rs1799983, rs5498, rs3093030, rs1800469, rs6679497, rs3829365 or rs1028728 polymorphisms analyzed located in or close to genes involved in postischemic neovascularization (*VEGFA*, *KDR*, *CCL2*, *ICAM1* and *POSTN*) or their haplotype combinations were associated with CCC development. In addition, in our cohort of patients we could not validate the association of the *NOS3* rs1799983, *HIF1A* rs11549465, *VEGFA* rs2010963 and rs699947, and *LGALS2* rs7291467 polymorphisms with CCC development reported by other authors. We and others have demonstrated the potential role of certain polymorphisms as factors associated with CCC \[[@CR5], [@CR21], [@CR28], [@CR45], [@CR46]\], but usually they have not been validated in other cohorts of patients. In addition, SNPs may influence collateral development not only individually, but also when acting together with other SNPs, through gene haplotype networks, as demonstrated by the role of several inflammatory gene haplotype networks in CCC \[[@CR65]\]. In conclusion, a validated SNP-based GWAS is needed to reveal and/or confirm the SNPs that predict coronary arteriogenic response.
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